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CriteriaAbstract Aim of the work: We attempt here to describe 2 cases of Behc¸et’s disease (BD) with
pulmonary vascular complications.
Case presentation: Two cases of Behc¸et’s disease with major vessel involvement are presented.
The ﬁrst case presented with hemoptysis and investigations revealed the presence of pulmonary
artery aneurysm (PAA). The patient received pulsed methylprednisolone 1 gm/day for 3 successive
days and pulse cyclophosphamide 600 mg monthly for 6 months, and oral maintenance therapy
1 mg/kg prednisolone daily. The patient’s symptoms improved within 2 weeks and a follow up
CT angiography after 1 year revealed normal pulmonary arteries. The second case presented with
dilated tortuous veins over the chest wall and was diagnosed to have superior vena cava (SVC)
obstruction. The patient was prescribed pulsed methylprednisolone 1 gm/day for 3 successive days
and pulse cyclophosphamide 600 mg/month for 6 months and oral prednisolone 1 mg/kg/day main-
tenance therapy, in addition to, oral warfarin therapy 5 mg/day to maintain his INR at 2.5. The
patient was discharged after stabilization of his condition.
Conclusion: Since a signiﬁcant proportion of patients develops complications in arterial and
venous vessels, vascular lesions should be included in the diagnostic criteria of BD. Challenges
remain to identify those patients at risk, to understand the cause and best treatment of thrombosis
in these patients, and to develop well tolerated and effective therapies to arrest or reverse the course
of vasculitis in BD.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
Open access under CC BY-NC-ND license.1. Introduction
Behc¸et’s disease (BD) is a chronic, relapsing, multisystemic dis-
order characterized by recurrent oro-genital ulcers and ocular
inﬂammation with cutaneous, musculoskeletal, vascular and
nervous system manifestations [1]. The etio-pathogenesis of
the disease remains obscure, although genetic predisposition,
environmental factors and immunological abnormalities have
been implicated [2,3]. BD has a worldwide distribution; how-
ever, it is mainly seen in Far East and Middle East countries.-NC-ND
 license.
Figure 1 CT pulmonary angiography showing aneurismal dila-
tation of the inferior lingular branch of the left pulmonary artery
(arrow), with partial thickness of its lumen.
Figure 2 Follow up CT pulmonary angiography after 1 year,
showing complete disappearance of the pulmonary aneurysm
(arrow).
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BD [4]. The age of disease onset is usually in the second or
third decade of life with almost equal male to female ratio.
However, the disease is more severe in men and in those with
onset before 25 years of age [5].
The diagnosis of BD is made on the basis of the criteria
proposed by the International Study Group (ISG) for Behc¸et
disease in 1990 [6]. According to the criteria, recurrent oral
ulceration must be present along with at least 2 of the fol-
lowing: recurrent genital ulceration, eye lesions, skin lesions
and a positive pathergy test. Vasculitis is thought to underlie
many of the clinical manifestations of BD. The vasculitis of
BD is distinctive because of involvement of both arteries and
veins of all sizes [7]. Large vessel vasculitis is seen in up to
40% of the patients and it was proposed to be one of the
diagnostic criteria of the disease [8,9]. Lower extremity vein
thrombosis is the most frequent manifestation of vascular
involvement, followed by vena cava thrombosis, pulmonary
artery aneurysms (PAA), Budd–Chiari syndrome, peripheral
artery aneurysms, dural sinus thrombosis and abdominal
aorta aneurysms [10]. Venous system involvement is more
common than arterial system involvement; however, rupture
of an arterial aneurysm remains a major cause of mortality
related to BD [11].
We attempt here to describe 2 cases of BD with pulmonary
vascular complications. It is important to recognize these
patients early as their prognosis is less favorable and they
are candidates for more aggressive treatment.
2. Case 1
A 37 year old male patient, occasional smoker, presented
complaining of high grade fever of 5 months duration associ-
ated with rigors and sweating with no diurnal variation,
3 months later the patient experienced recurrent attacks of
hemoptysis associated with dyspnea with no cough or chest
pain. During this period he developed recurrent oral and
genital ulcers, with no ocular manifestations or skin rash.
The patient sought medical advice and was diagnosed to
have chest infection. He received antibiotics with no
improvement. The patient was then referred to an expert
rheumatologist. On examination the patient was conscious
and alert, his blood pressure was 140/80, pulse was regular
with intact peripheral pulsation and temperature was
38.3 C. Systemic examination revealed no abnormality.
There were oral and genital ulcers. Pathergy test was nega-
tive and ophthalmologic examination was free. Laboratory
analysis showed: white blood count was 10.08 · 103/lL,
hemoglobin was 11.0 g/dL, hematocrit was 32.1% and eryth-
rocyte sedimentation rate was 62 mm/h. The possibility of
BD was raised. Chest X-ray showed an opacity in the infe-
rior lobe of the left lung and CT pulmonary angiography
showed aneurismal dilatation of the inferior lingular branch
of the left pulmonary artery (Fig. 1).
The patient received pulsed methylprednisolone 1 gm/day
for 3 successive days and pulse cyclophosphamide 600 mg
monthly for 6 months, and oral maintenance therapy 1 mg/
kg prednisolone daily. The patient’s symptoms improved
within 2 weeks and a follow up CT angiography after 1 year
revealed normal pulmonary arteries. The patient is under fol-
low up schedule (Fig. 2).3. Case 2
A 37 year old male, heavy cigarette smoker, presented com-
plaining of painful swelling in the left arm, edema of the face
and eye lids of 8 months duration. This was associated with
the development of dilated veins on the front of the chest
and abdomen. During the past 3 years the patient gave a his-
tory of recurrent painful oral ulcers and multiple painful pap-
ules on the scrotum and inner aspects of the upper parts of
both thighs which then rupture leaving painful ulcers. He gave
no history of ocular manifestations. On examination the
patient was conscious and alert. His blood pressure was 130/
80, pulse was regular with intact peripheral pulsations and
temperature was 37 C. He had a puffy face and eye lids, con-
gested non pulsating neck veins, dilated veins on the front and
back of the chest and left shoulder ﬁlling from above down-
wards with no redness or tenderness (Fig. 3). He also had white
scars on the scrotum and crusted lesions on the inner sides of
the upper thighs. Systemic examination was free. Ophthalmo-
logical examination was free and pathergy test was negative.
Laboratory tests showed white blood count was 8.2 · 103/
lL, hemoglobin was 12.0 g/dL, hematocrit was 32.1% and
Figure 3 Dilated veins on the front of the chest.
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diagnosed to have Behc¸et’s disease. CT pulmonary & aortic
angiography were ordered which showed partial superior vena
cava (SVC) obliteration at the level of the aortic arch with
proximal and distal recanalization (Fig. 4). Numerous medias-
tinal and to a lesser degree chest wall collaterals were noted.
The patient was prescribed pulsed methylprednisolone
1 gm/day for 3 successive days and pulse cyclophosphamide
600 mg/month for 6 months and oral prednisolone 1 mg/kg/
day maintenance therapy, in addition to, oral warfarin therapy
5 mg/day to maintain his INR at 2.5. The patient was dis-
charged after stabilization of his condition; however he did
not follow his condition in our hospital.
4. Discussion
We report 2 rare cases of BD with pulmonary vascular involve-
ment. The ﬁrst patient presented with pulmonary arterial aneu-
rysm secondary to vasculitis, fulﬁlling the BD criteria.
Pulmonary artery aneurysms (PAA) are observed in less
than 5% of patients with BD [11] and are the most lethal com-
plication of the disease [10]. As in our patient, PAA usually
present with hemoptysis, accompanied by chest pain, cough
and dyspnea in varying degrees. Rupture of an aneurysm with
erosion into a bronchus has been suggested as an explanationFigure 4 CT pulmonary and aortic angiography showing partial SV
recanalization.for the hemoptysis [12]. Fever, fatigue and an increased acute
phase response characterize the early stages of these aneurysms
[7]. The presence of hemoptysis may lead to the misdiagnosis
of tuberculosis. Considering the rarity of pulmonary emboli
in Behc¸et’s disease, hemoptysis should be viewed with a very
high index of suspicion for PAA [7]. PAA aneurysms, usually
bilateral, develop preferentially in the large and medium sized
pulmonary arteries [12]. Thrombi within the aneurysms and
coexisting venous thrombosis are usually present (81%). Intra-
cardiac thrombus formation and arterial disease in other sites
may further complicate the clinical picture [12,13].
A plain chest radiograph usually shows round hilar or
peripheral opacities, frequently multiple and bilateral. Spiral
CT scan of the lungs shows the aneurysms and the accompany-
ing thromboses in most of the cases and may also be used in
monitoring therapy. Multislice CT and MR angiography are
other imaging alternatives [14,15].
The mechanism of vascular lesions remains unknown. It is
commonly believed that complicated interactions among T
cells, neutrophils, and antigen-presenting cells are implicated
in the immunity-related pathogenesis of BD. Inﬂammatory
obliterative endarteritis of the vasa vasorum, endothelial cell
swelling and mononuclear perivascular inﬁltration cause
destruction of media, arterial wall weakening and aneurysm
formation [16].
Pulmonary artery aneurysms (PAA) carry a bad prognosis
in patients with BD; Hamuryudan et al. reported that 12 of 24
patients (50%) died after an average of 10 months after the
onset of hemoptysis [17]. A variety of treatment modalities,
such as surgery, anticoagulation, embolization, and more
effectively of them all immunosuppression especially with
cyclophosphamide and high dose steroids have been used in
the management of PAA with limited success [7,10,18].
In a study of 534 patients with BD, only 8 suffered from
PAA, but 6 of these died despite immunosuppressive treatment
or surgery [6]. However, a more recent study by Hamuryudan
et al., presenting the data of 26 patients having BD with PAA,
showed an improved survival rate of 62%; secondary to
prompt diagnosis of PAA and early commencement of
long term immunosuppression with cyclophosphamide and
steroids [12].
In one case report, a 39-year-old man with BD presented
with hemoptysis with computed tomography and magnetic res-
onance angiography revealing multiple, bilateral PAAs; aC obliteration at the level of aortic arch with proximal and distal
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resulted in complete resolution of his radiologic ﬁndings [19].
Our patient was treated with methylprednisolone and
cyclophosphamide combination therapy followed by predniso-
lone maintenance therapy. We have observed complete clinical
and radiological improvement within 1 year.
Our second patient presented with the SVC syndrome
caused by obliteration of the SVC lumen. Superior vena cava
thrombosis is a rare but easily identiﬁed manifestation of
BD. With adequate collateral vessels, patients may tolerate
chronic caval occlusion for many years, but deaths have been
reported as a result of extensive thrombosis, treatment, hem-
optysis, or other vascular causes including, very rarely, pul-
monary embolus [20]. Superior vena caval occlusion leads to
cyanosis and swelling of the face and upper extremities with
congested non pulsating jugular veins [21].
The management of venous disease in BD is controversial.
Some groups use routine anticoagulation whereas others
utilize immunosuppressives. A combination of the two
approaches is also occasionally advised [22]. The absence of
embolization, the lack of a consistent coagulation abnormality
[23,24] coupled with tightly adherent thrombi to the vessel wall
suggesting an inﬂammatory pathology [25] favor the use of
immunosuppressives but controlled data are lacking.
Our patient with PAA did not fulﬁll the ISG criteria for the
diagnosis of BD. Several cases of BD who did not fulﬁll the
ISG criteria have been reported [26,27]. It has been suggested
that separate diagnostic criteria be established for BD with
vascular involvement [28]. Since a signiﬁcant proportion of
patients develops complications in arterial and venous vessels,
vascular lesions should be included in the diagnostic criteria of
BD. Challenges remain to identify those patients at risk, to
understand the cause and best treatment of thrombosis in these
patients, and to develop well tolerated and effective therapies
to arrest or reverse the course of vasculitis in BD.
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